Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232881 · ClinicalTrials.gov registry record
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
A clinical trial, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- 27
- Enrollment target
NCT01232881: Clinical Trial study, sponsored by Hoosier Cancer Research Network.
NCT01232881 is a clinical trial that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01232881 was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- 27 participants
- Enrollment target
Study Summary
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Interventions
- PROCEDURE Tumor Sample
- PROCEDURE Serum Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-11 |
Why NCT01232881 stopped before completion
NCT01232881 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Tumor Sample is the first listed.
NCT01232881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01232881 about?
NCT01232881 is a clinical study titled "Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer". This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
What is the current status of trial NCT01232881?
This trial is currently terminated. The enrollment target is 27 participants. The study started on 2009-08. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01232881?
The interventions under investigation include: Tumor Sample (PROCEDURE), Serum Sample (PROCEDURE).
Who is sponsoring clinical trial NCT01232881?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia